Anda belum login :: 18 Apr 2025 17:59 WIB
Detail
ArtikelHematopoietic stem cell transplantation for primary cutaneous ?d T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma  
Oleh: Gibson, Juliet Fraser ; Alpdogan, Onder ; Subtil, Antonio ; Girardi, Michael ; Wilson, Lynn D.
Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: JAAD: Journal of the American Academy of Dermatology (keterangan: ada di ClinicalKey) vol. 72 no. 06 (Jun. 2015), page 1010–1015.
Topik: ?-d; hematopoietic stem cell transplantation; primary cutaneous ?d T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; T-cell lymphoma
Ketersediaan
  • Perpustakaan FK
    • Nomor Panggil: J15.K
    • Non-tandon: 1 (dapat dipinjam: 0)
    • Tandon: tidak ada
    Lihat Detail Induk
Isi artikelBackground The panniculitic T-cell lymphomas (TCLs) comprise 2 distinct entities, aß subcutaneous panniculitis-like TCL (SPTCL) and the ?d cutaneous TCLs with pannicular involvement primary cutaneous ?d (PCGD)-TCL. Although outcomes for most patients with SPTCL are favorable, those with PCGD-TCLs generally have an inferior outcome, and treatment strategies have not been well defined. Allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be a potentially curative strategy in aggressive TCLs and in refractory and advanced-stage mycosis fungoides. Objective We sought to analyze the outcomes of HSCT for panniculitic cutaneous TCL. Results Fourteen patients (4 SPTCL, 10 PCGD-TCL) presented with primarily pannicular T-cell infiltrates. Seven patients underwent allogeneic HSCT from matched-related donors and matched-unrelated donors of which 4 (57%) are alive (1 SPTCL, 3 PCGD-TCL) at 7.8, 6.9, 6.2, and 0.25 years. Two patients underwent autologous HSCT (1 SPTCL, 1 PCGD-TCL) and both are alive at a median follow-up of 1.91 years. Limitations This study is limited by its retrospective nature and small sample size because of the rarity of SPTCL and PCGD-TCL. Conclusion Aggressive therapy followed by allogeneic HSCT is a promising treatment modality for patients with PCGD-TCL.
Opini AndaKlik untuk menuliskan opini Anda tentang koleksi ini!

Kembali
design
 
Process time: 0 second(s)